The transition of the class of glyphozine medicines from direct distribution to pharmaceutical distribution, in application of the 2024 Budget Law, was one of the points discussed at the AIFA-Regions working group meeting held on 14 April at the Agency’s headquarters. This was a fruitful meeting, as it was decided to share the calculation method to assess the economic impact of the class change for this category of drugs, primarily used as anti-diabetics.

The exchange with the Regions will continue on the expenditure data processed following the conclusion of the renegotiation process for the prices of this class of medicinal products, which is expected shortly.